Insider trades
Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.
- $1.5B bought by 353 insiders at 214 companies
- $3.3B sold by 278 insiders outside a trading plan
- $7.9B sold by 834 insiders under 10b5-1 plans
- 10 companies where two or more insiders bought (30 days)
Biggest buys
Past month, each insider's filings added up.
-
LENLennarBerkshire Hathaway Inc.10% owner, +1 joint filer$383M
-
CRBGCorebridge FinancialLife Insurance Co Nippon10% owner$233M
-
KODKodiak SciencesBaker Bros. Advisors LPDirector, +5 joint filers$157M
-
SAFXXCF GlobalEEME Energy SPV I, LLC10% owner$142M
-
GPIGroup 1 AutomotiveConifer Management, L.L.C.10% owner$97.8M
-
UUUUniversal Safety ProductsMilton C Ault IIIDirector$92.5M
-
GMEGameStopRyan CohenCEO$50.4M
-
BORRBorr DrillingTor Olav TroimDirector$43M
-
PAMPampa EnergiaMarcos Marcelo MindlinDirector$35.1M
-
GGRGogoroChung-Yao YinDirector$35.1M
Biggest sales
Past month, each insider's filings added up. Planned sales are marked.
-
IHTInnSuites Hospitality TrustJames F WirthCEO$4.2B
-
MDLNMedlineGIC Private Ltd10% owner, +2 joint filers$996M
-
ESTCElasticSteven SchuurmanDirector$323M
-
TALOTalos EnergyEmpresarial De Capitales S.a. De C.v. Control10% owner$253M
-
AVGOBroadcomHenry SamueliDirector$250M
-
THTarget HospitalityTDR Capital II Investments LP10% owner, +9 joint filers$202M
-
ANETArista NetworksJayshree UllalCEO$166M
-
KNTKKinetikISQ Global Fund II GP LLC10% owner, +4 joint filers$134M
-
CRWDCrowdStrikeBurt W. PodbereCFO$125M
-
NBISNebius GroupOphir NaveCOO$118M
Cluster buying
Companies where two or more insiders bought on the open market in the last 30 days, most buyers first
-
Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more
-
Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more
-
R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more
-
Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more
-
Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more
-
John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more
-
Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more
-
Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more
-
Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO
-
Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director
PHVS insider trades
Every open-market buy and sale in PHVS, one row per filing, newest first
-
Viviane Monges DirectorPHVSPharvarisSale$396K 11,969 shares at $33.05 69% of stakeTraded Sep 23 Filed Sep 25
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisSale$29K 800 shares at $36.19 0.7% of stakeTraded Sep 22 Filed Sep 24
-
David W. Nassif CFOPHVSPharvarisSale$219K 6,000 shares at $36.47 5% of stakeTraded Sep 21 Filed Sep 23
-
Peng Lu PresidentPHVSPharvarisSale$3.5M 100,000 shares at $35.00 61% of stakeTraded Sep 17 Filed Sep 21
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisSale$7M 200,000 shares at $35.00 64% of stakeTraded Sep 17 Filed Sep 21
-
Elisabeth Bjork DirectorPHVSPharvarisSale$2M 52,500 shares at $37.89 78% of stakeTraded Sep 17 Filed Sep 21
-
Robert Glassman DirectorPHVSPharvarisPlanned sale$559K 14,493 shares at $38.56 58% of stakeTraded Sep 17 Filed Sep 21
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisSale$765K 20,000 shares at $38.27 21% of stakeTraded Sep 17 Filed Sep 21
-
Stefan Andreas Abele Chief Technical Ops OfficerPHVSPharvarisSale$1.8M 46,400 shares at $38.17 54% of stakeTraded Sep 15 Filed Sep 17
-
Robert Glassman DirectorPHVSPharvarisPlanned sale$332K 8,667 shares at $38.27 45% of stakeTraded Sep 15 Filed Sep 17
-
Wim Souverijns Chief Commercial OfficerPHVSPharvarisPlanned sale$1M 26,090 shares at $39.23 40% of stakeTraded Sep 14–15 Filed Sep 16
-
Peng Lu PresidentPHVSPharvarisPlanned sale$602K 15,000 shares at $40.13 19% of stakeTraded Sep 11 Filed Sep 15
-
Berndt Modig CEOPHVSPharvarisPlanned sale$90K 2,291 shares at $39.40 1.8% of stakeTraded Sep 14 Filed Sep 15
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisPlanned sale$1.1M 30,000 shares at $38.30 35% of stakeTraded Sep 10 Filed Sep 14
-
Robert Glassman DirectorPHVSPharvarisPlanned sale$300K 8,000 shares at $37.55 43% of stakeTraded Sep 9 Filed Sep 11
-
Peng Lu PresidentPHVSPharvarisPlanned sale$610K 15,000 shares at $40.68 19% of stakeTraded Sep 8 Filed Sep 9
-
Berndt Modig CEOPHVSPharvarisPlanned sale$80K 2,292 shares at $34.77 1.7% of stakeTraded Aug 14 Filed Aug 18
-
Berndt Modig CEOPHVSPharvarisPlanned sale$80K 2,292 shares at $34.97 1.7% of stakeTraded Jul 13 Filed Jul 15
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisPlanned sale$1.3M 37,600 shares at $35.41 11% of stakeTraded Jun 29–30 Filed Jul 1
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisPlanned sale$2.7M 76,172 shares at $35.39Traded Jun 29–30 Filed Jul 1
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisPlanned sale$162K 4,600 shares at $35.12Traded Jun 25 Filed Jun 29
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisPlanned sale$84K 2,400 shares at $35.10 0.7% of stakeTraded Jun 29 Filed Jun 29
-
Peng Lu Chief Medical OfficerPHVSPharvarisPlanned sale$1M 29,700 shares at $34.30 31% of stakeTraded Jun 25–26 Filed Jun 29
-
Peng Lu Chief Medical OfficerPHVSPharvarisPlanned sale$10K 300 shares at $34.00 0.5% of stakeTraded Jun 18 Filed Jun 23
-
Berndt Modig CEOPHVSPharvarisPlanned sale$71K 2,291 shares at $31.07 1.7% of stakeTraded Jun 15 Filed Jun 17
-
Anna Nijdam Principal Accounting OfficerPHVSPharvarisSale$82K 2,670 shares at $30.87 5.5% of stakeTraded Jun 4 Filed Jun 8
-
Viviane Monges DirectorPHVSPharvarisSale$293K 9,667 shares at $30.29 64% of stakeTraded May 21 Filed May 26
-
Anna Nijdam Principal Accounting OfficerPHVSPharvarisSale$225K 7,330 shares at $30.70 13% of stakeTraded May 21–22 Filed May 26
-
David W. Nassif CFOPHVSPharvarisSale$303K 10,000 shares at $30.31 7.7% of stakeTraded May 21 Filed May 26
-
Elisabeth Bjork DirectorPHVSPharvarisPlanned sale$293K 10,000 shares at $29.32 40% of stakeTraded May 20 Filed May 22
-
Berndt Modig CEOPHVSPharvarisPlanned sale$67K 2,292 shares at $29.22 1.6% of stakeTraded May 18 Filed May 20
-
Robert Glassman DirectorPHVSPharvarisSale$298K 10,000 shares at $29.82 49% of stakeTraded May 15 Filed May 19
-
Stefan Andreas Abele Chief Technical Ops OfficerPHVSPharvarisSale$261K 8,748 shares at $29.82 20% of stakeTraded May 15 Filed May 19
-
Wim Souverijns Chief Commercial OfficerPHVSPharvarisPlanned sale$299K 10,000 shares at $29.92 18% of stakeTraded May 15 Filed May 19
-
Peng Lu Chief Medical OfficerPHVSPharvarisPlanned sale$427K 14,166 shares at $30.17 18% of stakeTraded May 1 Filed May 5
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisPlanned sale$997K 32,900 shares at $30.29 8.5% of stakeTraded Apr 29–30 Filed May 1
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisPlanned sale$1.5M 48,300 shares at $30.23Traded Apr 29–30 Filed May 1
-
Peng Lu Chief Medical OfficerPHVSPharvarisPlanned sale$566K 18,733 shares at $30.21 22% of stakeTraded Apr 29–30 Filed May 1
-
Johannes Gerardus Christiaan Petrus Schikan DirectorPHVSPharvarisPlanned sale$213K 7,100 shares at $30.05 1.8% of stakeTraded Apr 22–23 Filed Apr 24
-
Anne Lesage Chief Early DevelopmentPHVSPharvarisPlanned sale$442K 14,700 shares at $30.05Traded Apr 22–23 Filed Apr 24
-
Peng Lu Chief Medical OfficerPHVSPharvarisPlanned sale$213K 7,101 shares at $30.05 9.7% of stakeTraded Apr 22–23 Filed Apr 24
-
Berndt Modig CEOPHVSPharvarisPlanned sale$66K 2,292 shares at $28.60 1.6% of stakeTraded Apr 16 Filed Apr 20
-
Berndt Modig CEOPHVSPharvarisPlanned sale$647K 23,333 shares at $27.74 14% of stakeTraded Apr 9 Filed Apr 10
About this data
- Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
- Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
- A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
- Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
- We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.